Key facts
- Zene’s last known valuation is $5.8M (Mar 2024).
- It has raised $2.3M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Incubate Fund, Spiral Capital (Tokyo), LINK-J, Miraidoa Tohoku, Panasonic Kurashi Visionary Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Zene
- ·The full record, as it builds
Funding rounds
No funding rounds for Zene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zene
Developer of a genome analysis platform designed to investigate each person's individuality and discover a new self by examining genetic information. The company's platform uses technology to analyze life-long health risks and conditions that are affected by genes with accuracy, enabling health insurance associations, local government, and national health insurance companies to reduce medical costs by providing the information people need to stay healthy from genomic information.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Employees
- 10
- Website
- zene.co.jp/
- Ownership
- Privately Held (backing)
Zene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zene in its N-PORT filings yet. We sweep new filings monthly.